NuVasive, Inc. (NASDAQ:NUVA) shares gapped down before the market opened on Wednesday . The stock had previously closed at $55.26, but opened at $55.28. NuVasive shares last traded at $56.27, with a volume of 27711 shares.

A number of brokerages have weighed in on NUVA. Credit Suisse Group began coverage on NuVasive in a research note on Monday, December 17th. They set an “outperform” rating and a $66.00 price target on the stock. Cantor Fitzgerald reissued a “hold” rating and set a $50.00 price target on shares of NuVasive in a research note on Monday, February 11th. ValuEngine lowered NuVasive from a “buy” rating to a “hold” rating in a research note on Friday, December 7th. UBS Group reduced their price target on NuVasive from $54.00 to $42.00 and set a “sell” rating on the stock in a research note on Tuesday, January 8th. Finally, Morgan Stanley reduced their price target on NuVasive from $73.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. NuVasive presently has an average rating of “Hold” and an average price target of $65.33.

The company has a quick ratio of 1.92, a current ratio of 3.44 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 2.07 and a beta of 1.22.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Wednesday, February 20th. The medical device company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.06. NuVasive had a return on equity of 14.60% and a net margin of 1.13%. The firm had revenue of $288.30 million during the quarter, compared to the consensus estimate of $290.85 million. During the same period in the prior year, the firm earned $0.56 EPS. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. Analysts predict that NuVasive, Inc. will post 2.25 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Enlightenment Research LLC acquired a new stake in shares of NuVasive during the fourth quarter valued at about $25,000. Royce & Associates LP acquired a new stake in shares of NuVasive during the fourth quarter valued at about $25,000. Bessemer Group Inc. acquired a new stake in shares of NuVasive during the fourth quarter valued at about $50,000. Contravisory Investment Management Inc. acquired a new stake in shares of NuVasive during the fourth quarter valued at about $114,000. Finally, Ffcm LLC grew its stake in shares of NuVasive by 191.2% during the fourth quarter. Ffcm LLC now owns 2,391 shares of the medical device company’s stock valued at $118,000 after acquiring an additional 1,570 shares in the last quarter.

WARNING: “NuVasive (NUVA) Shares Gap Down to $55.28” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/nuvasive-nuva-shares-gap-down-to-55-28/2891879.html.

NuVasive Company Profile (NASDAQ:NUVA)

NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Story: Determine Your Level of Risk Tolerance

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.